Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories is viewed favorably because management is signaling a meaningful margin reset, with a mid-teens operating margin objective for 2028-2029 versus a modeled 13% in 2029, suggesting substantial operating leverage from restructuring and cost discipline. The company also appears to be stabilizing across end markets and product lines, with ddPCR now about 70% consumables and process chromatography sequentially stable, reducing the risk around the 2026 guide. In addition, its ~33% Sartorius stake offers significant embedded asset value and added optionality as the controlling Trust terminates in mid-2028, while valuation still reflects a discount to peers despite improving fundamentals.

Bio-Rad Laboratories is facing a negative setup because investors may continue to discount its sales and margin trajectory if end-market recovery in life science tools remains delayed after years of false starts. The company also risks further share losses in ddPCR to Qiagen, while its mixed M&A track record and exposure to a potential shift from wet-lab research toward software/AI could pressure structural growth. On top of that, governance remains a concern because the Schwartz family controls the two-class voting structure, and downside cases already assume further multiple erosion plus a heavier discount on the Sartorius stake, with 8x EBITDA implying $290 or $222 under deeper cuts.